Alembic Pharmaceuticals has informed that the company has successfully completed an unannounced onsite Bioequivalence inspection conducted by United States Food and Drug Administration (‘USFDA’) at the Company’s Bioequivalence Facility located in Vadodara, Gujarat, with no Form 483 observations. The unannounced onsite USFDA Bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026.
The above information is a part of company’s filings submitted to BSE.